The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine resistance before disease progression in HR-positive, HER2-negative advanced breast cancer.
- Imaging discovery could accelerate drug development February 27, 2025
- Could novel 3D printing method enhance intestinal drug delivery? February 26, 2025
- Greener method for ethylene oxide manufacture identified February 25, 2025
- NICE recommends novel immunotherapy for leukaemia February 24, 2025
- First-in-human data for gene therapy signals potential in childhood blindness February 21, 2025
- Stabilising Europe’s generic medicine supply February 20, 2025
- FDA Accepts U.S. Biologics License Application for AVT06, Alvotech and Teva’s Proposed Aflibercept Biosimilar February 24, 2025
- FDA Approves First Rapid-Acting Insulin Biosimilar Product for the Treatment of Diabetes February 19, 2025
- IP Litigator Publishes Goodwin Partners’ BPCIA Research February 18, 2025
- UK’s MHRA Grants Marketing Authorization for Chikungunya Vaccine February 17, 2025
- Regulatory Updates on Samsung’s Denosumab Biosimilars February 17, 2025
- Available for Preorder: The 2025 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers February 26, 2025
- Drug Channels News Roundup, February 2025: Part D vs. Pharmacies, Accumulator Madness, Wholesaler Vertical Integration, IRA vs. MDs, and a 340B Cartoon February 25, 2025
- From Data Gaps to Revenue Gains: Harnessing the Power of Comprehensive Data to Drive GTN February 21, 2025
- Vanishing Act: Why Small Pharmacies Exited Medicare Part D Networks for 2025 February 18, 2025
- Compliance is Futile Without Transparency: 340B, MDRP, MFP Overlap Lead to Iceberg Ahead February 14, 2025
- Why Plan Sponsors and PBMs Are Still Falling Hard for Copay Maximizers February 12, 2025
- Today’s Rare Disease Launches Require the Right Specialty Pharmacy Partner February 7, 2025